You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Intratumoral Stromal Content in Lobular Breast Cancer: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Oncology
Contributor: Ulrik Narbe

High intratumoral stromal content is related to worse outcomes in several types of cancer. However, its prognostic role in breast cancer seems to differ between different subtypes. High intratumoral stromal content is a negative prognostic marker in triple-negative breast cancer, while the opposite is the case for estrogen-receptor-positive breast cancer, in which higher stromal content is indicative of a better prognosis. Most lobular breast cancers are estrogen-receptor-positive, and the tumor tissue has a clearly defined histological appearance, often with a high intratumoral stromal content. 

  • intratumoral stroma
  • lobular breast cancer
  • long-term prognosis

1. Introduction

Invasive lobular cancer (ILC) is the second most common type of breast cancer after invasive ductal cancer of no special type (NST) and constitutes 10 to 15% of all breast cancer [1]. Compared to NST, ILC is characterized by lower cellular content and displays a different and characteristic infiltrative growth pattern, where the cancer cells typically grow in thin lines (i.e., ‘single file’) into the surrounding tissue [2][3]. The intratumoral stromal content is higher in ILC compared to tubular breast cancer and NST [4]. Moreover, several differences regarding the tumor microenvironment in the stroma have been identified between ILC and NST [5]. Studies have shown that stromal cells (e.g., pericytes and fibroblasts) integrate with cancer cells and can affect tumor progression via paracrine signaling, which stimulates tumor growth and angiogenesis [6]. Tumor infiltrating lymphocytes (TILs) in the intratumoral stroma interact with cancer cells via complex immune-mediated mechanisms, and the presence of TILs is associated with prognostic outcome in breast cancer [7][8]. To date, there is no strict consensus on how to assess the relationship between stromal content and cancer cells in tumor tissue. Most commonly, a manual assessment of the percentage of stromal content in relation to tumor cellularity in a representative area of the tumor tissue using hematoxylin–eosin-stained sections is applied, and a cut-off value of 50% intratumoral stromal content is used as a threshold for grading tumors as ‘high stroma’ or ‘low stroma’ [9][10][11]. An alternative method of grading is the tumor stroma ratio (TSR), where the epithelial area is divided by the stromal area [4]. The intratumoral stromal content has also been evaluated using digital image analysis and machine learning algorithms [4].
More than 10 years ago, Mesker et al. demonstrated that intratumoral stromal content is an independent prognostic factor for colon cancer [12]. The study showed that tumors with high stromal content are correlated with a worse prognosis in terms of both overall and disease-free survival. Since then, further studies have reported that high intratumoral stromal content corresponds to a worse outcome in various other tumor types (e.g., non-small cell lung cancer, hepatocellular carcinoma, and esophagus cancer) [13]. In line with these results, several studies on breast cancer have shown that high intratumoral stromal content is a negative prognostic factor, especially in triple-negative breast cancer [10][14][15][16][17][18][19]. However, in studies investigating estrogen-receptor-positive (ER+) breast cancer, the opposite pattern was indicated, namely that higher stromal content is associated with a better prognosis [4][11]. The prognostic role of intratumoral stromal content can, therefore, differ greatly between different subtypes of breast cancer. The relevance of considering different subtypes was also indicated in one study where there was no evidence for the prognostic importance of intratumoral stromal content in inflammatory breast cancer [20]. Most previous studies have included all the histological subtypes of breast cancer and, hence, only a small fraction correspond to ILCs. To the researchers best knowledge, there are no previous studies investigating the prognostic role of intratumoral stromal content exclusively in ILC. The vast majority of ILCs are classified as estrogen-receptor-positive and human-epidermal growth-factor-receptor-2 negative (ER+/HER2−). The unique infiltrative growth patterns of ILC, with typically high stromal content in relation to low tumor cellularity, make the study of this cancer as an individual entity even more relevant.

2. Intratumoral Stromal Content in Lobular Breast Cancer

In this study of a well-defined population of patients with ER+/HER2− ILC, high intratumoral stromal content was found to be a ‘good-prognostic’ factor associated with lower BCM based on a follow-up time of 10 years. The evidence was weaker when the follow-up was prolonged to 25 years and in multivariable analyses with 10- and 25-year follow-ups. High intratumoral stromal content was closely associated with NHG, which, together with Ki67, nodal status, and patient age, comprised the most important prognostic factors in the multivariable analysis. Interestingly, none of the 13 NHG 3 tumors presented high intratumoral stromal content, which was in stark contrast to the large proportion of high-stroma tumors among NHG 1 tumors (19 of 22).
These results are in line with those of two previous reports on ER+ breast cancer showing that patients with high-stroma tumors have a better prognosis than those with low-stroma tumors [4][11]. Additionally, in one of these studies, the same strong association between high intratumoral stromal content and low NHG was reported [4]. However, the prognostic importance of intratumoral stromal content in ILC was not specifically addressed in these studies and the number of included patients with ILC was low (i.e., in Millar et al., 31 out of 403 and, in Downey et al., 6 out of 180). In studies that included all histological subtypes or exclusively analyzed triple-negative breast cancer, the patients with high-stroma tumors were repeatedly associated with a worse prognosis [10][14][15][16][17][18][19]. The discrepancy in the results obtained in different studies suggests that the prognostic role of intratumoral stromal content may differ in different subgroups. The aim of the present study was, therefore, to specifically study ER+/HER2− ILC, which is a well-defined subgroup including most patients with ILC. In exploratory analyses, the prognostic effects of the intratumoral stromal content in patients with tumors classified as luminal A-like, luminal B-like, and NHG 2 were essentially the same as those in the whole cohort. In line with previous ILC studies [21][22], the majority (81%) of the patients in this cohort were classified as NHG 2, an intermediate prognostic group for whom long-term outcomes are unpredictable and, therefore, complementary prognostic tools are warranted. In the researchers subgroup analysis, patients with NHG 2 ILC, the patients could be subdivided into two comparable groups of high vs. low intratumoral stromal content (high stroma: n = 62; low stroma: n = 83) with different outcomes.
A recent study by Vangangelt et al. showed that intratumoral stromal content increases with age, and that this content is not an independent factor in multivariable analysis for patients above or at the age of 70 years [23]. In the present study, only three breast-cancer-related deaths were recorded in this older age group. Consequently, age dependency could not be further examined. Furthermore, adjuvant systemic therapies vary between different studies. In a study by Roeke et al., the association between high intratumoral stromal content and an impaired outcome was most distinct in the patients treated with adjuvant endocrine therapy [9]. Although the evaluation of intratumoral stromal content seems to be easily assessable, with satisfactory kappa values reported (0.68–0.85; [9][10][14]), differences in the evaluations of intratumoral stromal content on hematoxylin–eosin-stained sections may still be critical (e.g., the area selected, the size of the selected area, and the number of assessed areas) [10][11][24][25]. Digital image analysis and machine learning algorithms may provide a more reproducible approach than manual scoring [4]. Further studies analyzing the method agreement and prognostic validity between manual and digital assessment in the same set of tumor samples would be of interest.
Although prognostic information can be derived from assessment of the intratumoral stroma, it is important to consider that this is a simplistic way of looking at the highly complex underlying tumor microenvironment. The importance of distinguishing between different dominant stromal components (collagen, fibroblasts, or lymphocytes) and combining the stromal content in the primary tumor with that in lymph-node metastases has also been indicated [26][27]. Differences between the ILC and NST microenvironments regarding cancer-associated fibroblasts and intratumoral vessels have been observed [5]. In ILC, the expression of fibroblast-activation protein alpha and fibroblast-specific protein 1/S100A4 was higher in both the tumor and stromal cells than in NST [28]. In tubular breast cancer and NST, CD34+ fibroblasts are absent in the intratumoral stroma [29][30], whereas, in ILC, these fibroblasts are present in approximately two thirds of the cases [31]. A study by Westhoff et al. showed that a loss of CD34+ fibroblasts in ILC was associated with an unfavorable prognosis [31].
The prognostic significance of TILs in TNBC and HER2+ breast cancer has been extensively studied, and the presence of TILs in the intratumoral stroma is associated with a more favorable prognosis [7][8]. In ER+/HER2− breast cancer, a subtype normally less immunogenic than TNBC and HER+ breast cancer, the prognostic role of TILs is not fully elucidated, although several studies suggest that the presence of TILs is associated with a less favorable prognosis [7]. Furthermore, in ILC, only a small fraction of the tumors have TILs, and the levels are generally lower than in NST [32][33]. The prognostic role of TILs in ILC has hitherto been sparsely investigated; however, two recent studies indicate that the presence of TILs is an unfavorable prognostic factor in this histological subtype [33][34]. In a study by Millar et al., patients with TNBC and a combination of low intratumoral stromal content and low levels of TILs had an extraordinarily poor prognosis [4]. In the present study, no assessment of TILs was performed. A large and sufficiently powered study investigating the prognostic impact between the intratumoral stromal content and TILs in ILC would be encouraged.
In line with the researchers results, a protein-based stromal signature was used to identify a special good prognostic subtype of breast cancer called ‘reactive’. Members of this subtype are mainly ER+/HER2−, either lobular or tubular, and feature a high number of stromal cells [35]. The possible predictive value of intratumoral stroma was indicated in one study using gene-expression data, showing that increased stromal gene expression can predict resistance to preoperative chemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide [36]. Finally, in a recent publication, reactive stroma was found to be associated with trastuzumab resistance in HER2-positive primary breast cancer [37].
The re-evaluation of exclusively pure ER+/HER2− ILCs by breast pathologists is a strength of the present study. Another important advantage is this study’s long-term follow-up since the lobular histological subtype is associated with a risk of late recurrences that can occur >10 years after the initial primary diagnosis. The patients with ILC in this cohort were, to a great extent, not treated with any systemic adjuvant therapy, which afforded an opportunity to study the prognostic importance of the intratumoral stroma in a state of only minor interference with the original tumor biology. A limitation of the present study is the relatively small sample size, which is associated with a low power. Future studies exploring the clinical importance of intratumoral stromal content in ILC are warranted and should preferably be performed using larger and well-defined patient materials.

This entry is adapted from the peer-reviewed paper 10.3390/cancers14040941

References

  1. Christgen, M.; Steinemann, D.; Kühnle, E.; Länger, F.; Gluz, O.; Harbeck, N.; Kreipe, H. Lobular breast cancer: Clinical, molecular and morphological characteristics. Pathol. Res. Pract. 2016, 212, 583–597.
  2. Martinez, V.; Azzopardi, J.G. Invasive lobular carcinoma of the breast: Incidence and variants. Histopathology 1979, 3, 467–488.
  3. Barroso-Sousa, R.; Metzger-Filho, O. Differences between invasive lobular and invasive ductal carcinoma of the breast: Results and therapeutic implications. Ther. Adv. Med. Oncol. 2016, 8, 261–266.
  4. Millar, E.K.; Browne, L.H.; Beretov, J.; Lee, K.; Lynch, J.; Swarbrick, A.; Graham, P.H. Tumour Stroma Ratio Assessment Using Digital Image Analysis Predicts Survival in Triple Negative and Luminal Breast Cancer. Cancers 2020, 12, 3749.
  5. Nakagawa, S.; Miki, Y.; Miyashita, M.; Hata, S.; Takahashi, Y.; Rai, Y.; Sagara, Y.; Ohi, Y.; Hirakawa, H.; Tamaki, K.; et al. Tumor microenvironment in invasive lobular carcinoma: Possible therapeutic targets. Breast Cancer Res. Treat. 2016, 155, 65–75.
  6. Pietras, K.; Östman, A. Hallmarks of cancer: Interactions with the tumor stroma. Exp. Cell Res. 2010, 316, 1324–1331.
  7. El Bairi, K.; Haynes, H.R.; Blackley, E.; Fineberg, S.; Shear, J.; Turner, S.; De Freitas, J.R.; Sur, D.; Amendola, L.C.; Gharib, M.; et al. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer 2021, 7, 150.
  8. Salgado, R.; Denkert, C.; Demaria, S.; Sirtaine, N.; Klauschen, F.; Pruneri, G.; Wienert, S.; Van den Eynden, G.; Baehner, F.L.; Penault-Llorca, F.; et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. Ann. Oncol. 2015, 26, 259–271.
  9. Roeke, T.; Sobral-Leite, M.; Dekker, T.J.A.; Wesseling, J.; Smit, V.T.H.B.M.; Tollenaar, R.A.E.M.; Schmidt, M.K.; Mesker, W.E. The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: A validation study. Breast Cancer Res. Treat. 2017, 166, 435–445.
  10. Moorman, A.; Vink, R.; Heijmans, H.; Van Der Palen, J.; Kouwenhoven, E. The prognostic value of tumour-stroma ratio in triple-negative breast cancer. Eur. J. Surg. Oncol. 2012, 38, 307–313.
  11. Downey, C.L.; Simpkins, S.A.; White, J.; Holliday, D.L.; Jones, J.L.; Jordan, L.B.; Kulka, J.; Pollock, S.; Rajan, S.S.; Thygesen, H.H.; et al. The prognostic significance of tumour–stroma ratio in oestrogen receptor-positive breast cancer. Br. J. Cancer 2014, 110, 1744–1747.
  12. Mesker, W.E.; Junggeburt, J.M.C.; Szuhai, K.; De Heer, P.; Morreau, H.; Tanke, H.J.; Tollenaar, R.A.E.M. The Carcinoma–Stromal Ratio of Colon Carcinoma Is an Independent Factor for Survival Compared to Lymph Node Status and Tumor Stage. Cell. Oncol. 2007, 29, 387–398.
  13. Wu, J.; Liang, C.; Chen, M.; Su, W. Association between tumor-stroma ratio and prognosis in solid tumor patients: A systematic review and meta-analysis. Oncotarget 2016, 7, 68954–68965.
  14. De Kruijf, E.M.; Van Nes, J.G.; Van De Velde, C.J.; Putter, H.; Smit, V.T.; Liefers, G.J.; Kuppen, P.J.; Tollenaar, R.A.; Mesker, W.E. Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res. Treat. 2011, 125, 687–696.
  15. Kramer, C.J.H.; Vangangelt, K.M.H.; Van Pelt, G.W.; Dekker, T.; Tollenaar, R.A.E.M.; Mesker, W.E. The prognostic value of tumour–stroma ratio in primary breast cancer with special attention to triple-negative tumours: A review. Breast Cancer Res. Treat. 2019, 173, 55–64.
  16. Dekker, T.J.; Van De Velde, C.J.; Van Pelt, G.W.; Kroep, J.R.; Julien, J.P.; Smit, V.T.; Tollenaar, R.A.; Mesker, W.E. Prognostic significance of the tumor-stroma ratio: Validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854). Breast Cancer Res. Treat. 2013, 139, 371–379.
  17. Vangangelt, K.M.H.; Van Pelt, G.W.; Engels, C.C.; Putter, H.; Liefers, G.J.; Smit, V.T.H.B.M.; Tollenaar, R.A.E.M.; Kuppen, P.J.K.; Mesker, W.E. Prognostic value of tumor-stroma ratio combined with the immune status of tumors in invasive breast carcinoma. Breast Cancer Res. Treat. 2018, 168, 601–612.
  18. Vangangelt, K.M.H.; Green, A.R.; Heemskerk, I.M.F.; Cohen, D.; Van Pelt, G.W.; Sobral-Leite, M.; Schmidt, M.K.; Putter, H.; Rakha, E.A.; Tollenaar, R.A.; et al. The prognostic value of the tumor–stroma ratio is most discriminative in patients with grade III or triple-negative breast cancer. Int. J. Cancer 2020, 146, 2296–2304.
  19. Gujam, F.J.A.; Edwards, J.; Mohammed, Z.M.A.; Going, J.; McMillan, D. The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer. Br. J. Cancer 2014, 111, 157–165.
  20. Downey, C.L.; Thygesen, H.H.; Sharma, N.; Shaaban, A.M. Prognostic significance of tumour stroma ratio in inflammatory breast cancer. SpringerPlus 2015, 4, 68.
  21. Metzger Filho, O.; Giobbie-Hurder, A.; Mallon, E.; Gusterson, B.; Viale, G.; Winer, E.P.; Thurlimann, B.; Gelber, R.D.; Colleoni, M.; Ejlertsen, B.; et al. Relative Effectiveness of Letrozole Compared with Tamoxifen for Patients with Lobular Carcinoma in the BIG 1-98 Trial. J. Clin. Oncol. 2015, 33, 2772–2779.
  22. Rakha, E.A.; El-Sayed, M.E.; Powe, D.G.; Green, A.; Habashy, H.O.; Grainge, M.; Robertson, J.F.; Blamey, R.; Gee, J.; Nicholson, R.I.; et al. Invasive lobular carcinoma of the breast: Response to hormonal therapy and outcomes. Eur. J. Cancer 2008, 44, 73–83.
  23. Vangangelt, K.M.H.; Kramer, C.J.H.; Bastiaannet, E.; Putter, H.; Cohen, D.; Van Pelt, G.W.; Rakha, E.A.; Green, A.R.; Tollenaar, R.A.E.M.; Mesker, W.E. The intra-tumoural stroma in patients with breast cancer increases with age. Breast Cancer Res. Treat. 2020, 179, 37–45.
  24. Mesker, W.E.; Dekker, T.J.; De Kruijf, E.M.; Engels, C.C.; Van Pelt, G.W.; Smit, V.T.; Tollenaar, R.A. Comment on: The prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer. Br. J. Cancer 2015, 112, 1832–1833.
  25. Downey, C.L.; Simpkins, S.A.; Holliday, D.L.; Jones, J.L.; Jordan, L.B.; Kulka, J.; Hanby, A.M.; Speirs, V. Reponse to: Comment on, ‘Tumour-stroma ratio (TSR) in oestrogen-positive breast cancer patients’. Br. J. Cancer 2015, 112, 1833–1834.
  26. Ahn, S.; Cho, J.; Sung, J.-Y.; Lee, J.E.; Nam, S.J.; Kim, K.-M.; Cho, E.Y. The prognostic significance of tumor-associated stroma in invasive breast carcinoma. Tumor Biol. 2012, 33, 1573–1580.
  27. Vangangelt, K.M.; Tollenaar, L.S.; Van Pelt, G.W.; De Kruijf, E.M.; Dekker, T.; Kuppen, P.J.; Tollenaar, R.A.; Mesker, W.E. The prognostic value of tumor-stroma ratio in tumor-positive axillary lymph nodes of breast cancer patients. Int. J. Cancer 2018, 143, 3194–3200.
  28. Park, C.K.; Jung, W.H.; Koo, J.S. Expression of cancer-associated fibroblast-related proteins differs between invasive lobular carcinoma and invasive ductal carcinoma. Breast Cancer Res. Treat. 2016, 159, 55–69.
  29. Barth, P.J.; Ebrahimsade, S.; Ramaswamy, A.; Moll, R. CD34+ fibrocytes in invasive ductal carcinoma, ductal carcinoma in situ, and benign breast lesions. Virchows Arch. 2002, 440, 298–303.
  30. Ramaswamy, A.; Moll, R.; Barth, P.J. CD34 + fibrocytes in tubular carcinomas and radial scars of the breast. Virchows Arch. 2003, 443, 536–540.
  31. Westhoff, C.C.; Jank, P.; Jacke, C.O.; Albert, U.-S.; Ebrahimsade, S.; Barth, P.J.; Moll, R. Prognostic relevance of the loss of stromal CD34 positive fibroblasts in invasive lobular carcinoma of the breast. Virchows Arch. 2020, 477, 717–724.
  32. McCart Reed, A.E.; Kalinowski, L.; Simpson, P.T.; Lakhani, S.R. Invasive lobular carcinoma of the breast: The increasing importance of this special subtype. Breast Cancer Res. 2021, 23, 6.
  33. Desmedt, C.; Salgado, R.; Fornili, M.; Pruneri, G.; Van Den Eynden, G.; Zoppoli, G.; Rothé, F.; Buisseret, L.; Garaud, S.; Willard-Gallo, K.; et al. Immune Infiltration in Invasive Lobular Breast Cancer. JNCI J. Natl. Cancer Inst. 2018, 110, 768–776.
  34. Tille, J.-C.; Vieira, A.; Saint-Martin, C.; Djerroudi, L.; Furhmann, L.; Bidard, F.-C.; Kirova, Y.; Tardivon, A.; Reyal, F.; Carton, M.; et al. Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma. Mod. Pathol. 2020, 33, 2198–2207.
  35. Dennison, J.B.; Shahmoradgoli, M.; Liu, W.; Ju, Z.; Meric-Bernstam, F.; Perou, C.M.; Sahin, A.A.; Welm, A.L.; Oesterreich, S.; Sikora, M.J.; et al. High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype. Clin. Cancer Res. 2016, 22, 5068–5078.
  36. Farmer, P.; Bonnefoi, H.; Anderle, P.; Cameron, D.A.; Wirapati, P.; Becette, V.; André, S.; Piccart-Gebhart, M.; Campone, M.; Brain, E.; et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med. 2009, 15, 68–74.
  37. Sonnenblick, A.; Salmon-Divon, M.; Salgado, R.; Dvash, E.; Pondé, N.; Zahavi, T.; Salmon, A.; Loibl, S.; Denkert, C.; Joensuu, H.; et al. Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer. Int. J. Cancer 2020, 147, 266–276.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Academic Video Service
Feedback